Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $325.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price hoisted by equities research analysts at Chardan Capital from $300.00 to $325.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s target price would suggest a potential upside of 25.29% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research note on Monday, March 31st. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research note on Monday, March 31st. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Finally, Royal Bank of Canada boosted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $319.17.

Alnylam Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ ALNY opened at $259.39 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The business’s 50 day moving average is $248.21 and its two-hundred day moving average is $254.99. Alnylam Pharmaceuticals has a 52-week low of $144.73 and a 52-week high of $304.39. The firm has a market cap of $33.74 billion, a price-to-earnings ratio of -119.53 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts’ expectations of $584.32 million. During the same quarter last year, the firm posted ($0.16) earnings per share. The company’s quarterly revenue was up 20.2% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Pushkal Garg sold 1,561 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $398,320.37. Following the completion of the transaction, the chief marketing officer now directly owns 13,537 shares in the company, valued at $3,454,236.29. This represents a 10.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,392 shares of company stock valued at $1,875,627. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Grandfield & Dodd LLC boosted its holdings in Alnylam Pharmaceuticals by 27.8% in the 1st quarter. Grandfield & Dodd LLC now owns 3,032 shares of the biopharmaceutical company’s stock valued at $819,000 after purchasing an additional 659 shares in the last quarter. Cullen Frost Bankers Inc. raised its position in Alnylam Pharmaceuticals by 0.7% in the first quarter. Cullen Frost Bankers Inc. now owns 10,717 shares of the biopharmaceutical company’s stock worth $2,894,000 after acquiring an additional 78 shares in the last quarter. Parcion Private Wealth LLC acquired a new stake in Alnylam Pharmaceuticals in the first quarter valued at $202,000. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth $540,000. Finally, Larson Financial Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 77.7% during the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 87 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.